Authors


Stephen J. Schuster, MD

Latest:

Exploring the Use of Tisagenlecleucel for Patients With Lymphoma

Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.


Zachary Epstein-Peterson, MD

Latest:

What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.


Susana Banerjee, MBBS, PhD

Latest:

Implications of the MEDIOLA Trial Results in Relapsed Ovarian Cancer

Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.


Tim Smith

Latest:

Relationship Between Plaque Psoriasis and Cancer Risk Identified

In a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.


Nazli Dizman, MD

Latest:

Analyzing the Role of Gut Microbiome in Renal Cell Carcinoma

Nazli Dizman, MD, internal medicine resident at Yale Department of Internal Medicine, discusses the role of the gut microbiome in cancers like renal cell carcinoma.


Regina Barragan-Carrillo, MD

Latest:

Study Links Prior Thymectomy to Higher Rate of Nephrectomy in RCC

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.


Lucy Langer, MD

Latest:

Genetic Testing Empowers Better Cancer Care, Prevention, and Early Detection

Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.


Janelle Hart

Latest:

Advancing the Perioperative Management of Bladder Cancer

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.


Rachel V. Rose, JD, MBA

Latest:

Key Telehealth Factors to Monitor

When providing telehealth, providers must check individual state laws and policies regarding telehealth and providing telehealth across state lines. In sum, there is a lot to stay on top of in relation to telehealth.


Katherine B. Peters, MD, PhD

Latest:

INDIGO Trial Shows Potential of Vorasidenib in Low-Grade Glioma

Katherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.


Guenther Koehne, MD, PhD

Latest:

Reflections on Immunotherapies for Hematologic Malignancies From MCI’s Fifth Annual Summit

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.



Sabarish Ram Ayyappan, MD

Latest:

Final Analysis of ELM-2 Shows Promise of Odronextamab in R/R DLBCL

Sabarish Ram Ayyappan, MD, discusses findings from the final analysis of the phase 2 ELM-2 trial of odronextamab in a cohort of patients with relapsed/refractory diffuse large B-cell lymphoma.


Kayla Giannetti, MSN, APRN-CNP

Latest:

Frailty May Impact Hospital Stay Duration After Stem Cell Transplants

Kayla Giannetti, MSN, APRN-CNP, discusses a study presented at the 2024 Transplantation and Cellular Therapy Tandem Meetings investigating the link between patient frailty and stem cell transplants.


Nina Svenson, PhD

Latest:

Overcoming Resistance in Gastrointestinal Cancers

Immune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.



Robert Galamaga, DO

Latest:

Kidney Cancer Awareness Month: The Evolving Landscape of RCC Management

Robert Galamaga, DO, reviews single-agent and combination targeted therapy advances in renal cell carcinoma for Kidney Cancer Awareness Month.


Uday R. Popat, MD

Latest:

Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD

Uday R. Popat, MD, discusses the role of ruxolitinib as treatment of patients with graft-versus-host-disease.


Justin M. Watts, MD

Latest:

Pevonedistat/Azacitidine Combo Demonstrates Encouraging EFS Data in Phase 2 Trial in MDS

Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.



Sachin Gupta

Latest:

Solutions Are Emerging to Help MIDs Efficiently Manage Prior Authorizations

Medically integrated dispensing pharmacies in oncology often deal with complex PAs that can inhibit delivery of timely, quality care and consume staff resources.


Benjamin H. Lowentritt, MD, FACS

Latest:

Apalutamide Produces Deep PSA Response vs Enzalutamide in mCSPC

Benjamin H. Lowentritt, MD, FACS, discusses findings from a United States real-world study of patients with metastatic castration-sensitive prostate cancer treated with apalutamide or enzalutamide.


Samer A. Srour, MD, MS

Latest:

CAR T Cells Engineered to Target Solid Tumors

Samer A. Srour, MB, ChB, MS, discusses the design of ALLO-316, an agent investigated in the phase 2 TRAVERSE trial for patients with renal cell carcinoma.


Alexander Spira, MD, PhD

Latest:

MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC

Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.


Kristina Mirabeau-Beale, MD, MPH

Latest:

Breast Cancer Awareness Month: What to Know for Different Types of Breast Cancer

For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.


Kaveh Zakeri, MD, MAS

Latest:

JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.


Jen Buhay, PhD

Latest:

Precision Medicine Will Drive New Standards of Care in the Post–COVID-19 World

Once the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.


Rina Lokaj

Latest:

Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC

In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.


Ronald L. Paquette, MD

Latest:

The Role of Age in Bone Marrow and Stem Cell Transplants for MDS

Ronald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.


David Zhen, MD

Latest:

The Future of Upper Gastric Cancer Treatment

David Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.